glp-1 receptor agonist antipsychotic weight gain study The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials Efficacy and Safety of GLP-1
Description
Rare cases of Stevens-Johnsons syndrome have been reported with sitagliptin
Drugs that suppress appetite will have a huge impact on multiple markets if they deliver on current expectations
However, these drugs were never originally designed for long-term obesity control
Weight-Loss Drug Frenzy Cements Novo Nordisk as Europes Most Valuable Company
The frequency varies among clinical trials, although it usually ranges between 15 and 50% (Table 1)
